1. Home
  2. MYGN vs NUV Comparison

MYGN vs NUV Comparison

Compare MYGN & NUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • NUV
  • Stock Information
  • Founded
  • MYGN 1991
  • NUV 1987
  • Country
  • MYGN United States
  • NUV United States
  • Employees
  • MYGN N/A
  • NUV N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • NUV Trusts Except Educational Religious and Charitable
  • Sector
  • MYGN Health Care
  • NUV Finance
  • Exchange
  • MYGN Nasdaq
  • NUV Nasdaq
  • Market Cap
  • MYGN 2.0B
  • NUV 1.8B
  • IPO Year
  • MYGN 1995
  • NUV N/A
  • Fundamental
  • Price
  • MYGN $18.16
  • NUV $8.91
  • Analyst Decision
  • MYGN Buy
  • NUV
  • Analyst Count
  • MYGN 12
  • NUV 0
  • Target Price
  • MYGN $28.18
  • NUV N/A
  • AVG Volume (30 Days)
  • MYGN 783.2K
  • NUV 464.9K
  • Earning Date
  • MYGN 11-07-2024
  • NUV 01-01-0001
  • Dividend Yield
  • MYGN N/A
  • NUV 3.96%
  • EPS Growth
  • MYGN N/A
  • NUV N/A
  • EPS
  • MYGN N/A
  • NUV N/A
  • Revenue
  • MYGN $802,200,000.00
  • NUV N/A
  • Revenue This Year
  • MYGN $13.95
  • NUV N/A
  • Revenue Next Year
  • MYGN $9.71
  • NUV N/A
  • P/E Ratio
  • MYGN N/A
  • NUV N/A
  • Revenue Growth
  • MYGN 14.78
  • NUV N/A
  • 52 Week Low
  • MYGN $16.00
  • NUV $7.86
  • 52 Week High
  • MYGN $29.30
  • NUV $9.08
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 24.60
  • NUV 41.48
  • Support Level
  • MYGN $16.86
  • NUV $8.79
  • Resistance Level
  • MYGN $18.57
  • NUV $8.98
  • Average True Range (ATR)
  • MYGN 0.99
  • NUV 0.06
  • MACD
  • MYGN -0.39
  • NUV -0.01
  • Stochastic Oscillator
  • MYGN 16.49
  • NUV 37.50

About MYGN Myriad Genetics Inc.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

About NUV Nuveen Municipal Value Fund Inc.

Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.

Share on Social Networks: